APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antipyretic Medicine for Infants and Young Children

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antipyretic Medicine for Infants and Young Children Market Outlook and Growth Opportunities 2026

29 December 2025209 pages

Choose your research edition.

Industry ResearchAntipyretic Medicine for Infants and Young Children Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Antipyretic Medicine for Infants and Young Children Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Antipyretic Medicine for Infants and Young Children Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antipyretic Medicine for Infants and Young Children Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Antipyretic Medicine for Infants and Young Children Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Antipyretic Medicine for Infants and Young Children market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antipyretic Medicine for Infants and Young Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antipyretic Medicine for Infants and Young Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antipyretic Medicine for Infants and Young Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antipyretic Medicine for Infants and Young Children market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antipyretic Medicine for Infants and Young Children market include Anqiu Lu'an, Atabay, Farmson, Granules Biocause, Granules India, IOLCP, Mallinckrodt, Novacyl and SKPL, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antipyretic Medicine for Infants and Young Children market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antipyretic Medicine for Infants and Young Children and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antipyretic Medicine for Infants and Young Children revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antipyretic Medicine for Infants and Young Children market.

Antipyretic Medicine for Infants and Young Children Segment by Company

Anqiu Lu'an

Atabay

Farmson

Granules Biocause

Granules India

IOLCP

Mallinckrodt

Novacyl

SKPL

Strides Shasun

Temad

Anhui BBCA Likang

Anhui Fubore

Hebei Jiheng

Xinhua Pharmaceutical

Zhejiang Kangle

Antipyretic Medicine for Infants and Young Children Segment by Type

Acetaminophen

Ibuprofen

Other

Antipyretic Medicine for Infants and Young Children Segment by Application

Online Sales

Offline Sales

Antipyretic Medicine for Infants and Young Children Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antipyretic Medicine for Infants and Young Children status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antipyretic Medicine for Infants and Young Children key companies, revenue, market share, and recent developments.

3. To split the Antipyretic Medicine for Infants and Young Children breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antipyretic Medicine for Infants and Young Children market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antipyretic Medicine for Infants and Young Children significant trends, drivers, influence factors in global and regions.

6. To analyze Antipyretic Medicine for Infants and Young Children competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antipyretic Medicine for Infants and Young Children market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antipyretic Medicine for Infants and Young Children and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antipyretic Medicine for Infants and Young Children.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antipyretic Medicine for Infants and Young Children industry.

Chapter 3: Detailed analysis of Antipyretic Medicine for Infants and Young Children company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antipyretic Medicine for Infants and Young Children in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antipyretic Medicine for Infants and Young Children in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antipyretic Medicine for Infants and Young Children Industry Trends Table 2. Antipyretic Medicine for Infants and Young Children Industry Drivers Table 3. Antipyretic Medicine for Infants and Young Children Industry Opportunities and Challenges Table 4. Antipyretic Medicine for Infants and Young Children Industry Restraints Table 5. Global Antipyretic Medicine for Infants and Young Children Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antipyretic Medicine for Infants and Young Children Revenue Share by Company (2021-2026) Table 7. Global Antipyretic Medicine for Infants and Young Children Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antipyretic Medicine for Infants and Young Children Key Company Manufacturing Base & Headquarters Table 9. Global Antipyretic Medicine for Infants and Young Children Company, Product Type & Application Table 10. Global Antipyretic Medicine for Infants and Young Children Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antipyretic Medicine for Infants and Young Children by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Acetaminophen Table 15. Significant Companies of Ibuprofen Table 16. Significant Companies of Other Table 17. Global Antipyretic Medicine for Infants and Young Children Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Antipyretic Medicine for Infants and Young Children Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Antipyretic Medicine for Infants and Young Children Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Type (2021-2026) Table 21. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Online Sales Table 23. Significant Companies of Offline Sales Table 24. Global Antipyretic Medicine for Infants and Young Children Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antipyretic Medicine for Infants and Young Children Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Antipyretic Medicine for Infants and Young Children Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Application (2021-2026) Table 28. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Application (2027-2032) Table 29. Global Antipyretic Medicine for Infants and Young Children Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Antipyretic Medicine for Infants and Young Children Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Region (2021-2026) Table 32. Global Antipyretic Medicine for Infants and Young Children Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Region (2027-2032) Table 34. Global Antipyretic Medicine for Infants and Young Children Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Antipyretic Medicine for Infants and Young Children Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Antipyretic Medicine for Infants and Young Children Sales Value Market Share by Country (2021-2026) Table 37. Global Antipyretic Medicine for Infants and Young Children Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Antipyretic Medicine for Infants and Young Children Sales Value Market Share by Country (2027-2032) Table 39. Anqiu Lu'an Company Information Table 40. Anqiu Lu'an Business Overview Table 41. Anqiu Lu'an Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Anqiu Lu'an Antipyretic Medicine for Infants and Young Children Product Portfolio Table 43. Anqiu Lu'an Recent Development Table 44. Atabay Company Information Table 45. Atabay Business Overview Table 46. Atabay Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Atabay Antipyretic Medicine for Infants and Young Children Product Portfolio Table 48. Atabay Recent Development Table 49. Farmson Company Information Table 50. Farmson Business Overview Table 51. Farmson Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Farmson Antipyretic Medicine for Infants and Young Children Product Portfolio Table 53. Farmson Recent Development Table 54. Granules Biocause Company Information Table 55. Granules Biocause Business Overview Table 56. Granules Biocause Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Granules Biocause Antipyretic Medicine for Infants and Young Children Product Portfolio Table 58. Granules Biocause Recent Development Table 59. Granules India Company Information Table 60. Granules India Business Overview Table 61. Granules India Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Granules India Antipyretic Medicine for Infants and Young Children Product Portfolio Table 63. Granules India Recent Development Table 64. IOLCP Company Information Table 65. IOLCP Business Overview Table 66. IOLCP Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. IOLCP Antipyretic Medicine for Infants and Young Children Product Portfolio Table 68. IOLCP Recent Development Table 69. Mallinckrodt Company Information Table 70. Mallinckrodt Business Overview Table 71. Mallinckrodt Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Mallinckrodt Antipyretic Medicine for Infants and Young Children Product Portfolio Table 73. Mallinckrodt Recent Development Table 74. Novacyl Company Information Table 75. Novacyl Business Overview Table 76. Novacyl Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novacyl Antipyretic Medicine for Infants and Young Children Product Portfolio Table 78. Novacyl Recent Development Table 79. SKPL Company Information Table 80. SKPL Business Overview Table 81. SKPL Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. SKPL Antipyretic Medicine for Infants and Young Children Product Portfolio Table 83. SKPL Recent Development Table 84. Strides Shasun Company Information Table 85. Strides Shasun Business Overview Table 86. Strides Shasun Antipyretic Medicine for Infants and Young Children Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Strides Shasun Antipyretic Medicine for Infants and Young Children Product Portfolio Table 88. Strides Shasun Recent Development Table 89. Temad Company Information Table 90. Temad Business Overview Table 91. Temad Antipyretic Medicine for Infants and Young Children Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Temad Antipyretic Medicine for Infants and Young Children Product Portfolio Table 93. Temad Recent Development Table 94. Anhui BBCA Likang Company Information Table 95. Anhui BBCA Likang Business Overview Table 96. Anhui BBCA Likang Antipyretic Medicine for Infants and Young Children Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Anhui BBCA Likang Antipyretic Medicine for Infants and Young Children Product Portfolio Table 98. Anhui BBCA Likang Recent Development Table 99. Anhui Fubore Company Information Table 100. Anhui Fubore Business Overview Table 101. Anhui Fubore Antipyretic Medicine for Infants and Young Children Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Anhui Fubore Antipyretic Medicine for Infants and Young Children Product Portfolio Table 103. Anhui Fubore Recent Development Table 104. Hebei Jiheng Company Information Table 105. Hebei Jiheng Business Overview Table 106. Hebei Jiheng Antipyretic Medicine for Infants and Young Children Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Hebei Jiheng Antipyretic Medicine for Infants and Young Children Product Portfolio Table 108. Hebei Jiheng Recent Development Table 109. Xinhua Pharmaceutical Company Information Table 110. Xinhua Pharmaceutical Business Overview Table 111. Xinhua Pharmaceutical Antipyretic Medicine for Infants and Young Children Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Xinhua Pharmaceutical Antipyretic Medicine for Infants and Young Children Product Portfolio Table 113. Xinhua Pharmaceutical Recent Development Table 114. Zhejiang Kangle Company Information Table 115. Zhejiang Kangle Business Overview Table 116. Zhejiang Kangle Antipyretic Medicine for Infants and Young Children Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Zhejiang Kangle Antipyretic Medicine for Infants and Young Children Product Portfolio Table 118. Zhejiang Kangle Recent Development Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Antipyretic Medicine for Infants and Young Children Product Image Figure 2. Global Antipyretic Medicine for Infants and Young Children Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antipyretic Medicine for Infants and Young Children Market Size (2021-2032) & (US$ Million) Figure 4. Global Antipyretic Medicine for Infants and Young Children Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Acetaminophen Image Figure 8. Ibuprofen Image Figure 9. Other Image Figure 10. Global Antipyretic Medicine for Infants and Young Children Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Antipyretic Medicine for Infants and Young Children Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Type (2021-2032) Figure 13. Online Sales Image Figure 14. Offline Sales Image Figure 15. Global Antipyretic Medicine for Infants and Young Children Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Antipyretic Medicine for Infants and Young Children Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Application (2021-2032) Figure 18. Global Antipyretic Medicine for Infants and Young Children Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032) & (US$ Million) Figure 21. North America Antipyretic Medicine for Infants and Young Children Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Antipyretic Medicine for Infants and Young Children Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Antipyretic Medicine for Infants and Young Children Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032) & (US$ Million) Figure 27. South America Antipyretic Medicine for Infants and Young Children Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Antipyretic Medicine for Infants and Young Children Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Acetaminophen
  • Ibuprofen
  • Other
Applications
  • Online Sales
  • Offline Sales
Companies covered
  • Anqiu Lu'an
  • Atabay
  • Farmson
  • Granules Biocause
  • Granules India
  • IOLCP
  • Mallinckrodt
  • Novacyl
  • SKPL
  • Strides Shasun
  • Temad
  • Anhui BBCA Likang
  • Anhui Fubore
  • Hebei Jiheng
  • Xinhua Pharmaceutical
  • Zhejiang Kangle

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antipyretic Medicine for Infants and Young Children Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antipyretic Medicine for Infants and Young Children Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antipyretic Medicine for Infants and Young Children Market Dynamics
  1. 2.1 Antipyretic Medicine for Infants and Young Children Industry Trends
  2. 2.2 Antipyretic Medicine for Infants and Young Children Industry Drivers
  3. 2.3 Antipyretic Medicine for Infants and Young Children Industry Opportunities and Challenges
  4. 2.4 Antipyretic Medicine for Infants and Young Children Industry Restraints
3 Antipyretic Medicine for Infants and Young Children Market by Company
  1. 3.1 Global Antipyretic Medicine for Infants and Young Children Company Revenue Ranking in 2025
  2. 3.2 Global Antipyretic Medicine for Infants and Young Children Revenue by Company (2021-2026)
  3. 3.3 Global Antipyretic Medicine for Infants and Young Children Company Ranking (2024-2026)
  4. 3.4 Global Antipyretic Medicine for Infants and Young Children Company Manufacturing Base and Headquarters
  5. 3.5 Global Antipyretic Medicine for Infants and Young Children Company Product Type and Application
  6. 3.6 Global Antipyretic Medicine for Infants and Young Children Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antipyretic Medicine for Infants and Young Children Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antipyretic Medicine for Infants and Young Children Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antipyretic Medicine for Infants and Young Children Market by Type
  1. 4.1 Antipyretic Medicine for Infants and Young Children Type Introduction
  2. 4.1.1 Acetaminophen
  3. 4.1.2 Ibuprofen
  4. 4.1.3 Other
  5. 4.2 Global Antipyretic Medicine for Infants and Young Children Sales Value by Type
  6. 4.2.1 Global Antipyretic Medicine for Infants and Young Children Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antipyretic Medicine for Infants and Young Children Sales Value by Type (2021-2032)
  8. 4.2.3 Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Type (2021-2032)
5 Antipyretic Medicine for Infants and Young Children Market by Application
  1. 5.1 Antipyretic Medicine for Infants and Young Children Application Introduction
  2. 5.1.1 Online Sales
  3. 5.1.2 Offline Sales
  4. 5.2 Global Antipyretic Medicine for Infants and Young Children Sales Value by Application
  5. 5.2.1 Global Antipyretic Medicine for Infants and Young Children Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antipyretic Medicine for Infants and Young Children Sales Value by Application (2021-2032)
  7. 5.2.3 Global Antipyretic Medicine for Infants and Young Children Sales Value Share by Application (2021-2032)
6 Antipyretic Medicine for Infants and Young Children Regional Value Analysis
  1. 6.1 Global Antipyretic Medicine for Infants and Young Children Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antipyretic Medicine for Infants and Young Children Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antipyretic Medicine for Infants and Young Children Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antipyretic Medicine for Infants and Young Children Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032)
  7. 6.3.2 North America Antipyretic Medicine for Infants and Young Children Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032)
  10. 6.4.2 Europe Antipyretic Medicine for Infants and Young Children Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antipyretic Medicine for Infants and Young Children Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032)
  16. 6.6.2 South America Antipyretic Medicine for Infants and Young Children Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antipyretic Medicine for Infants and Young Children Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antipyretic Medicine for Infants and Young Children Sales Value Share by Country, 2025 VS 2032
7 Antipyretic Medicine for Infants and Young Children Country-level Value Analysis
  1. 7.1 Global Antipyretic Medicine for Infants and Young Children Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antipyretic Medicine for Infants and Young Children Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antipyretic Medicine for Infants and Young Children Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antipyretic Medicine for Infants and Young Children Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antipyretic Medicine for Infants and Young Children Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antipyretic Medicine for Infants and Young Children Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antipyretic Medicine for Infants and Young Children Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Anqiu Lu'an
  2. 8.1.1 Anqiu Lu'an Company Information
  3. 8.1.2 Anqiu Lu'an Business Overview
  4. 8.1.3 Anqiu Lu'an Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Anqiu Lu'an Antipyretic Medicine for Infants and Young Children Product Portfolio
  6. 8.1.5 Anqiu Lu'an Recent Developments
  7. 8.2 Atabay
  8. 8.2.1 Atabay Company Information
  9. 8.2.2 Atabay Business Overview
  10. 8.2.3 Atabay Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Atabay Antipyretic Medicine for Infants and Young Children Product Portfolio
  12. 8.2.5 Atabay Recent Developments
  13. 8.3 Farmson
  14. 8.3.1 Farmson Company Information
  15. 8.3.2 Farmson Business Overview
  16. 8.3.3 Farmson Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Farmson Antipyretic Medicine for Infants and Young Children Product Portfolio
  18. 8.3.5 Farmson Recent Developments
  19. 8.4 Granules Biocause
  20. 8.4.1 Granules Biocause Company Information
  21. 8.4.2 Granules Biocause Business Overview
  22. 8.4.3 Granules Biocause Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Granules Biocause Antipyretic Medicine for Infants and Young Children Product Portfolio
  24. 8.4.5 Granules Biocause Recent Developments
  25. 8.5 Granules India
  26. 8.5.1 Granules India Company Information
  27. 8.5.2 Granules India Business Overview
  28. 8.5.3 Granules India Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Granules India Antipyretic Medicine for Infants and Young Children Product Portfolio
  30. 8.5.5 Granules India Recent Developments
  31. 8.6 IOLCP
  32. 8.6.1 IOLCP Company Information
  33. 8.6.2 IOLCP Business Overview
  34. 8.6.3 IOLCP Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  35. 8.6.4 IOLCP Antipyretic Medicine for Infants and Young Children Product Portfolio
  36. 8.6.5 IOLCP Recent Developments
  37. 8.7 Mallinckrodt
  38. 8.7.1 Mallinckrodt Company Information
  39. 8.7.2 Mallinckrodt Business Overview
  40. 8.7.3 Mallinckrodt Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mallinckrodt Antipyretic Medicine for Infants and Young Children Product Portfolio
  42. 8.7.5 Mallinckrodt Recent Developments
  43. 8.8 Novacyl
  44. 8.8.1 Novacyl Company Information
  45. 8.8.2 Novacyl Business Overview
  46. 8.8.3 Novacyl Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novacyl Antipyretic Medicine for Infants and Young Children Product Portfolio
  48. 8.8.5 Novacyl Recent Developments
  49. 8.9 SKPL
  50. 8.9.1 SKPL Company Information
  51. 8.9.2 SKPL Business Overview
  52. 8.9.3 SKPL Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  53. 8.9.4 SKPL Antipyretic Medicine for Infants and Young Children Product Portfolio
  54. 8.9.5 SKPL Recent Developments
  55. 8.10 Strides Shasun
  56. 8.10.1 Strides Shasun Company Information
  57. 8.10.2 Strides Shasun Business Overview
  58. 8.10.3 Strides Shasun Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Strides Shasun Antipyretic Medicine for Infants and Young Children Product Portfolio
  60. 8.10.5 Strides Shasun Recent Developments
  61. 8.11 Temad
  62. 8.11.1 Temad Company Information
  63. 8.11.2 Temad Business Overview
  64. 8.11.3 Temad Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Temad Antipyretic Medicine for Infants and Young Children Product Portfolio
  66. 8.11.5 Temad Recent Developments
  67. 8.12 Anhui BBCA Likang
  68. 8.12.1 Anhui BBCA Likang Company Information
  69. 8.12.2 Anhui BBCA Likang Business Overview
  70. 8.12.3 Anhui BBCA Likang Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Anhui BBCA Likang Antipyretic Medicine for Infants and Young Children Product Portfolio
  72. 8.12.5 Anhui BBCA Likang Recent Developments
  73. 8.13 Anhui Fubore
  74. 8.13.1 Anhui Fubore Company Information
  75. 8.13.2 Anhui Fubore Business Overview
  76. 8.13.3 Anhui Fubore Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Anhui Fubore Antipyretic Medicine for Infants and Young Children Product Portfolio
  78. 8.13.5 Anhui Fubore Recent Developments
  79. 8.14 Hebei Jiheng
  80. 8.14.1 Hebei Jiheng Company Information
  81. 8.14.2 Hebei Jiheng Business Overview
  82. 8.14.3 Hebei Jiheng Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hebei Jiheng Antipyretic Medicine for Infants and Young Children Product Portfolio
  84. 8.14.5 Hebei Jiheng Recent Developments
  85. 8.15 Xinhua Pharmaceutical
  86. 8.15.1 Xinhua Pharmaceutical Company Information
  87. 8.15.2 Xinhua Pharmaceutical Business Overview
  88. 8.15.3 Xinhua Pharmaceutical Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Xinhua Pharmaceutical Antipyretic Medicine for Infants and Young Children Product Portfolio
  90. 8.15.5 Xinhua Pharmaceutical Recent Developments
  91. 8.16 Zhejiang Kangle
  92. 8.16.1 Zhejiang Kangle Company Information
  93. 8.16.2 Zhejiang Kangle Business Overview
  94. 8.16.3 Zhejiang Kangle Antipyretic Medicine for Infants and Young Children Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Zhejiang Kangle Antipyretic Medicine for Infants and Young Children Product Portfolio
  96. 8.16.5 Zhejiang Kangle Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst